Literature DB >> 25671681

Conditional disease-free survival after surgical resection of gastrointestinal stromal tumors: a multi-institutional analysis of 502 patients.

Danielle A Bischof1, Yuhree Kim1, Rebecca Dodson1, M Carolina Jimenez2, Ramy Behman3, Andrei Cocieru4, Sarah B Fisher5, Ryan T Groeschl6, Malcolm H Squires5, Shishir K Maithel5, Dan G Blazer4, David A Kooby5, T Clark Gamblin6, Todd W Bauer7, Fayez A Quereshy2, Paul J Karanicolas3, Calvin H L Law3, Timothy M Pawlik1.   

Abstract

IMPORTANCE: Gastrointestinal stromal tumors (GISTs) are the most commonly diagnosed mesenchymal tumors of the gastrointestinal tract. The risk of recurrence following surgical resection of GISTs is typically reported from the date of surgery. However, disease-free survival (DFS) over time is dynamic and changes based on disease-free time already accumulated following surgery.
OBJECTIVES: To assess the comparative performance of established GIST recurrence risk prognostic scoring systems and to characterize conditional DFS following surgical resection of GISTs. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study of 502 patients who underwent surgery for a primary, nonmetastatic GIST between January 1, 1998, and December 31, 2012, at 7 major academic cancer centers in the United States and Canada. MAIN OUTCOMES AND MEASURES: Disease-free survival of the patients was classified according to 5 prognostic scoring systems, including the National Institutes of Health criteria, modified National Institutes of Health criteria, Memorial Sloan Kettering Cancer Center GIST nomogram, and American Joint Committee on Cancer gastric and nongastric categories. The concordance index (also known as the C statistic or the area under the receiver operating curve) of established GIST recurrence risk prognostic scoring systems. Conditional DFS estimates were calculated.
RESULTS: Overall 1-year, 3-year, and 5-year DFS following resection of GISTs was 95%, 83%, and 74%, respectively. All the prognostic scoring systems had fair prognostic ability. For all tumor sites, the American Joint Committee on Cancer gastric category demonstrated the best discrimination (C = 0.79). Using conditional DFS, the probability of remaining disease free for an additional 3 years given that a patient was disease free at 1 year, 3 years, and 5 years was 82%, 89%, and 92%, respectively. Patients with the highest initial recurrence risk demonstrated the greatest increase in conditional survival as time elapsed. CONCLUSIONS AND RELEVANCE: Conditional DFS improves over time following resection of GISTs. This is valuable information about long-term prognosis to communicate to patients who are disease free after a period following surgery.

Entities:  

Mesh:

Year:  2015        PMID: 25671681      PMCID: PMC4703090          DOI: 10.1001/jamasurg.2014.2881

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  18 in total

1.  Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up.

Authors:  Markku Miettinen; Leslie H Sobin; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2005-01       Impact factor: 6.394

2.  Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up.

Authors:  Markku Miettinen; Hala Makhlouf; Leslie H Sobin; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2006-04       Impact factor: 6.394

Review 3.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

4.  Conditional survival of 56,268 patients with breast cancer.

Authors:  D E Henson; L A Ries; M T Carriaga
Journal:  Cancer       Date:  1995-07-15       Impact factor: 6.860

5.  Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study.

Authors:  Geir Tryggvason; Hjörtur G Gíslason; Magnús K Magnússon; Jón G Jónasson
Journal:  Int J Cancer       Date:  2005-11-01       Impact factor: 7.396

Review 6.  Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.

Authors:  M Miettinen; J Lasota
Journal:  Virchows Arch       Date:  2001-01       Impact factor: 4.064

7.  Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden.

Authors:  Bengt Nilsson; Per Bümming; Jeanne M Meis-Kindblom; Anders Odén; Aydin Dortok; Bengt Gustavsson; Katarzyna Sablinska; Lars-Gunnar Kindblom
Journal:  Cancer       Date:  2005-02-15       Impact factor: 6.860

Review 8.  Diagnosis of gastrointestinal stromal tumors: A consensus approach.

Authors:  Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

9.  Conditional survival estimates in 34,963 patients with invasive carcinoma of the colon.

Authors:  R M Merrill; D E Henson; L A Ries
Journal:  Dis Colon Rectum       Date:  1998-09       Impact factor: 4.585

10.  Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.

Authors:  Jason S Gold; Mithat Gönen; Antonio Gutiérrez; Javier Martín Broto; Xavier García-del-Muro; Thomas C Smyrk; Robert G Maki; Samuel Singer; Murray F Brennan; Cristina R Antonescu; John H Donohue; Ronald P DeMatteo
Journal:  Lancet Oncol       Date:  2009-09-28       Impact factor: 41.316

View more
  24 in total

Review 1.  Statistical Methods for Conditional Survival Analysis.

Authors:  Sin-Ho Jung; Ho Yun Lee; Shein-Chung Chow
Journal:  J Biopharm Stat       Date:  2017-11-29       Impact factor: 1.051

2.  Changing Odds of Survival Over Time among Patients Undergoing Surgical Resection of Gallbladder Carcinoma.

Authors:  Stefan Buettner; Georgios Antonios Margonis; Yuhree Kim; Faiz Gani; Cecilia G Ethun; George A Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles R Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Shishir K Maithel; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2016-08-05       Impact factor: 5.344

3.  Clinicopathologic Characteristics and Optimal Surgical Treatment of Duodenal Gastrointestinal Stromal Tumor.

Authors:  Seung Jae Lee; Ki Byung Song; Young-Joo Lee; Song Cheol Kim; Dae Wook Hwang; Jae Hoon Lee; Sang Hyun Shin; Jae Woo Kwon; Seung Hyun Hwang; Chung Hyeun Ma; Gui Suk Park; Ye Jong Park; Kwang-Min Park
Journal:  J Gastrointest Surg       Date:  2018-08-21       Impact factor: 3.452

4.  Curative Surgical Resection of Adrenocortical Carcinoma: Determining Long-term Outcome Based on Conditional Disease-free Probability.

Authors:  Yuhree Kim; Georgios A Margonis; Jason D Prescott; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Jason A Glenn; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik
Journal:  Ann Surg       Date:  2017-01       Impact factor: 12.969

5.  Conditional probability of long-term survival after resection of hilar cholangiocarcinoma.

Authors:  Stefan Buettner; Georgios A Margonis; Yuhree Kim; Faiz Gani; Cecilia G Ethun; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles R Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Shishir K Maithel; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2016-04-24       Impact factor: 3.647

6.  Gastric and Small Intestine Gist: Results of 156 Cases in 20 Years.

Authors:  S Lopez Gordo; C Bettonica; M Miró; F Estremiana; H Aranda; L Farran
Journal:  J Gastrointest Cancer       Date:  2021-04-19

7.  Conditional survival analysis in Korean patients with gastric cancer undergoing curative gastrectomy.

Authors:  Jin Won Lee; Bandar Ali; Han Mo Yoo; Cho Hyun Park; Kyo Young Song
Journal:  BMC Cancer       Date:  2015-12-23       Impact factor: 4.430

8.  Comparison of Different Risk Classification Systems in 558 Patients with Gastrointestinal Stromal Tumors after R0-Resection.

Authors:  Michael Schmieder; Doris Henne-Bruns; Benjamin Mayer; Uwe Knippschild; Claudia Rolke; Matthias Schwab; Klaus Kramer
Journal:  Front Pharmacol       Date:  2016-12-27       Impact factor: 5.810

9.  Conditional survival estimate of acute-on-chronic hepatitis B liver failure: a dynamic prediction based on a multicenter cohort.

Authors:  Ming-Hua Zheng; Sheng-Jie Wu; Ke-Qing Shi; Hua-Dong Yan; Hai Li; Gui-Qi Zhu; Yao-Yao Xie; Fa-Ling Wu; Yong-Ping Chen
Journal:  Oncotarget       Date:  2015-09-15

10.  The Combination of Neoadjuvant Therapy and Surgical Resection: A Safe and Effective Treatment for Rectal Gastrointestinal Stromal Tumors.

Authors:  Yu Liu; Wenju Chang; Wentao Tang; Ye Wei; Tianyu Liu; Yijiao Chen; Meiling Ji; Fei Liang; Li Ren; Jianmin Xu
Journal:  Cancer Manag Res       Date:  2021-06-14       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.